<DOC>
	<DOCNO>NCT00004652</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether time period randomization endpoint longer short term pimozide therapy long term therapy patient Tourette syndrome . II . Determine whether tic severity , medication side effect , academic performance psychosocial function good short term pimozide therapy long term pimozide therapy .</brief_summary>
	<brief_title>Phase II Pilot Controlled Study Short Vs Longer Term Pimozide ( Orap ) Therapy Tourette Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This combined open label double blind randomize study . Patients receive pimozide ( open label ) orally stable level tic control achieve remains unchanged least 1 month . Then , patient randomize one two possible double blind treatment . In short term pimozide group , patient receive pimozide 2 week . Then , pimozide gradually replace inactive placebo within follow 10 week . Patients long term pimozide group receive pimozide . Patients continue treatment 12 month worsen tic behavioral symptom present increased dosage require . Patients experience exacerbation tic require increase dosage follow 1 year date entry .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Pimozide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics DSMIIIR criterion Tourette syndrome Chronic motor tic disorder tic sufficiently severe require neuroleptic therapy Prior/Concurrent Therapy No clonidine least 2 week neuroleptic ( e.g. , haloperidol , pimozide ) within 3 month prior study Stable dosage medication ( e.g. , antiobsessional , stimulant ) least 3 month prior study require</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Tourette syndrome</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>